Last reviewed · How we verify
Mometasone furoate dry powder inhaler
At a glance
| Generic name | Mometasone furoate dry powder inhaler |
|---|---|
| Also known as | Asmanex |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Asthma Research in Children and Adolescents
- A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524) (PHASE3)
- A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223) (PHASE2)
- A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828) (PHASE4)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880) (PHASE3)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone furoate dry powder inhaler CI brief — competitive landscape report
- Mometasone furoate dry powder inhaler updates RSS · CI watch RSS
- Organon and Co portfolio CI